Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG

Cancer Immunology, Immunotherapy

Volumn 65, Issue 10, 2016, Pages 1149-1158

  Confino, Hila ^a   Schmidt, Michael ^a   Efrati, Margalit ^a   Hochman, Ilan ^a   Umansky, Viktor ^b,c   Kelson, Itzhak ^a   Keisari, Yona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Alpha radiation; Brachytherapy; Immunotherapy; Myeloid derived suppressor cells; Regulatory T cells; Tumor ablation

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOLOGICAL ADJUVANT; RADIUM 224; SILDENAFIL; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; TUMOR ANTIGEN;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DIFFUSING ALPHA EMITTER RADIATION THERAPY; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LOCAL THERAPY; LOW DRUG DOSE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; SYSTEMIC THERAPY; TUMOR ABLATION; ABLATION THERAPY; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BRACHYTHERAPY; BREAST NEOPLASMS; CELL GROWTH; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; MYELOID-DERIVED SUPPRESSOR CELL; RADIATION RESPONSE; THERAPEUTIC USE; TUMOR CELL LINE; TUMOR VOLUME; UTILIZATION;

ABLATION TECHNIQUES; ADENOCARCINOMA; ALPHA PARTICLES; ANIMALS; ANTIGENS, NEOPLASM; BRACHYTHERAPY; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MYELOID-DERIVED SUPPRESSOR CELLS; OLIGODEOXYRIBONUCLEOTIDES; SILDENAFIL CITRATE; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 84982903433     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1878-6     Document Type: Article

References (44)

1. Corthay A (2014) Does the immune system naturally protect against cancer? Front Immunol 5:197 (eCollection)
2. Nobler MP (1969) The abscopal effect in malignant lymphoma and its relationship to lymphocyte circulation. Radiology 93:410–412
3. Demaria S, Ng B, Devitt ML et al (2004) Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58:862–870
4. Crittenden M, Kohrt H, Levy R et al (2015) Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 25:54–64
5. Frey B, Rubner Y, Kulzer L et al (2014) Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63:29–36
6. Arazi L, Cooks T, Schmidt M et al (2007) Treatment of solid tumours by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol 52:5025–5042
7. Cooks T, Schmidt M, Bittan H et al (2009) Local control of lung derived tumors by diffusing alpha-emitting atoms released from intratumoral wires loaded with radium-224. Int J Radiat Oncol Biol Phys 74:966–973
8. Horev-Drori G, Cooks T, Bittan H et al (2012) Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224 radium-loaded wires releasing alpha-emitting atoms. Transl Res 159:32–41
9. Cooks T, Tal M, Raab S et al (2012) Intratumoral 224Ra-loaded wires spread alpha-emitters inside solid human tumors in athymic mice achieving tumor control. Anticancer Res 32:5315–5321
10. Reitkopf-Brodutch S, Confino H, Schmidt M et al (2015) Ablation of experimental colon cancer by intratumoral 224Radium loaded wires is mediated by alpha particles released from atoms which spread in the tumor and can be augmented by chemotherapy. Int J Radiat Biol 91(2):179–186
11. Keisari Y, Hochman I, Confino H et al (2014) Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intra-tumoral electrochemical or alpha radiation treatments. Cancer Immunol Immunother 63:1–9
12. Confino H, Hochman I, Efrati M et al (2015) Induction of anti-tumor immunity against experimental metastatic tumors following tumor ablation by intratumoral Ra-224 loaded wires. Cancer Immunol Immunother 64:191–199
13. Prehn RT, Prehn LM (2008) The flip side of immune surveillance: immune dependency. Immunol Rev 222:341–356
14. North RJ (1984) Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother 16(3):175–181
15. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253–268
16. Tanchot C, Terme M, Pere H et al (2013) Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron 6:147–157
17. Banerjee A, Vasanthakumar A, Grigoriadis G (2013) Modulating T regulatory cells in cancer: how close are we? Immunol Cell Biol 91(5):340–349
18. Oleinika K, Nibbs RJ, Graham GJ et al (2013) Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 171:36–45
19. Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J (2010) Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev 29(4):569–579
20. Danilin S, Merkel AR, Johnson JR et al (2012) Myeloid—derived suppressor cells expand during breast cancer progression and promote tumor—induced bone destruction. Oncoimmunology 1(9):1484–1494
21. Carrio R, Torroella-Kouri M, Libreros S et al (2011) Decreased accumulation of immune regulatory cells is correlated to the antitumor effect of IFN-γ overexpression in the tumor. Int J Oncol 39:1619–1627
22. Youn JI, Nagaraj S, Gabrilovich MI (2008) Subset of myeloid—derived suppressor cells in tumor-bearing mice. J Immunol 181:5791–5802
23. Reginato E, Mroz P, Chung H et al (2013) Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. Br J Cancer 109:2167–2174
24. Meyer C, Sevko A, Ramacher M et al (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108:17111–17116
25. Bode C, Zhao G, Steinhagen F et al (2011) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10(4):499–511
26. Teitz-Tennenbaum S, Li Q, Rynkiewicz S et al (2003) Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63:8466–8475
27. Ahmed MM, Hodge JW, Guha C et al (2013) Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res 1:280–284
28. Gorin JB, Ménager J, Gouard S et al (2014) Antitumor immunity induced after α irradiation. Neoplasia 16:319–328
29. Casares N, Arribillaga L, Sarobe P et al (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931–5939
30. Walter S, Weinschenk T, Stenzl A et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261
31. Kusmartsev S, Cheng F, Yu B et al (2003) All- trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63:4441–4449
32. Iclozan C, Antonia S, Chiappori A et al (2013) Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 62(5):909–918
33. Kalathil S, Lugade AA, Miller A et al (2013) Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 73:2435–2444
34. Xu J, Escamilla J, Mok S et al (2013) CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 73:2782–2794
35. Schneider T, Sevko A, Heussel CP et al (2015) Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small cell lung cancer. Clin Exp Immunol 180:467–474
36. Bos PD, Plitas G, Rudra D et al (2013) Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 210(11):2435–2466
37. Levy MY, Sidana A, Chowdhury WH et al (2009) Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J Pharmacol Exp Ther 330(2):596–601
38. Tongu M, Harashima N, Monma H et al (2013) Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 62:383–391
39. Song X, Guo W, Cui J et al (2011) A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice. Int J Cancer 128(5):1129–1138
40. Chen X, Yang Y, Zhou Q et al (2014) Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer. PLoS one 9:e85398
41. Dewan MZ, Vanpouille-Box C, Kawashima N et al (2012) Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res 18:6668–6678
42. Paulos CM, Kaiser A, Wrzesinski C et al (2007) Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13:5280–5289
43. Patabiraman DR, Weinberg RA (2014) Tackling the cancer stem cells—what challenges do they pose? Nat Rev Drug Discov 13:497–512
44. Sgouros G, Song H (2008) Cancer stem cells targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis. Cancer Biother Radioparm 23:74–81